Skip to content

Efavirenz more durable than Kaletra over two years in treament-naive patients

Access to treatment associated with declining stigma in Botswana

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered

New data shed light on poor outcome in SMART study

Merck launches expanded access programme for integrase inhibitor

Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets

Abacavir/3TC backbone proves most durable for children over five years

High rates of TB after beginning ART in Africa — but decreases observed over time

Kaletra monotherapy - more encouraging results